Digest Network Come funziona
Network
/
Società
MO
Non verificato

MOMA Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
17/07/2025
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341, a Highly Potent and Selective Werner Helicase Inhibitor
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0
17/04/2025
Eventi
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0
01/04/2025
MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0
08/01/2025
Mercato del lavoro
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
MOMA Therapeutics Provides Corporate Update and Announces Exclusive License Agreement for Selective PARP1 Inhibitor
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0
19/08/2024
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0
25/06/2024
MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer
Fonte
MOMA Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0